Cellectis SA
(NASDAQ : CLLS)

( )
CLLS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.16%162.160.7%$1270.30m
LLYEli Lilly & Co. 0.50%334.461.1%$1111.09m
ABBVAbbVie, Inc. 0.01%140.301.9%$860.61m
PFEPfizer Inc. 0.16%43.180.9%$804.94m
BMYBristol-Myers Squibb Co. -0.04%70.211.0%$751.47m
MRKMerck & Co., Inc. -0.37%87.110.7%$695.02m
AZNAstraZeneca Plc 1.95%55.981.0%$393.72m
ALNYAlnylam Pharmaceuticals, Inc. 0.00%202.378.2%$224.83m
GSKGSK Plc 1.70%30.510.3%$212.06m
NVSNovartis AG 0.54%76.450.2%$201.99m
HZNPHorizon Therapeutics Plc 0.00%67.895.4%$188.70m
IDXXIDEXX Laboratories, Inc. 0.00%346.023.9%$184.33m
GBTGlobal Blood Therapeutics, Inc. 0.00%68.495.4%$178.81m
SRPTSarepta Therapeutics, Inc. 0.00%114.8212.4%$141.73m
AKROAkero Therapeutics, Inc. 0.00%39.260.0%$134.17m

Company Profile

Cellectis SA operates as a clinical stage biotechnological company. The firm operates through the segments: Therapeutics and Plants. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and monogenic diseases. The Plants segment focuses on using Calyxt's proprietary PlantSpringTM technology platform to engineer plant metabolism to produce innovative, high-value, and sustainable materials and products for use in helping customers meet their sustainability targets and financial goals. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.